Oruka Therapeutics Inc
ORKA32.120USD
+0.410+1.29%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.55BMarket Cap
46.19P/E TTM
More Details of Oruka Therapeutics Inc Company
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Oruka Therapeutics Inc Info
Ticker SymbolORKA
Company nameOruka Therapeutics Inc
IPO dateJul 21, 2000
CEOKlein (Lawrence Otto)
Number of employees28
Security typeOrdinary Share
Fiscal year-endJul 21
Address855 Oak Grove Ave.
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone16506067910
Websitehttps://orukatx.com/
Ticker SymbolORKA
IPO dateJul 21, 2000
CEOKlein (Lawrence Otto)
Company Executives of Oruka Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.10M
+29.17%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
213.08K
--
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Independent Director
Independent Director
108.32K
+27.08%
Dr. Joana Goncalves, M.D.
Dr. Joana Goncalves, M.D.
Chief Medical Officer
Chief Medical Officer
191.00
--
Ms. Kristine M. Ball
Ms. Kristine M. Ball
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Mr. Alan Lada
Mr. Alan Lada
IR Contact Officer
IR Contact Officer
--
--
Mr. Paul T. Quinlan
Mr. Paul T. Quinlan
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Independent Director
Independent Director
--
--
Mr. Arjun Agarwal
Mr. Arjun Agarwal
Senior Vice President - Finance, Treasurer
Senior Vice President - Finance, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.10M
+29.17%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
213.08K
--
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Independent Director
Independent Director
108.32K
+27.08%
Dr. Joana Goncalves, M.D.
Dr. Joana Goncalves, M.D.
Chief Medical Officer
Chief Medical Officer
191.00
--
Ms. Kristine M. Ball
Ms. Kristine M. Ball
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.95%
VR Adviser, LLC
8.57%
Fairmount Funds Management LLC
7.65%
Viking Global Investors LP
5.51%
Deep Track Capital LP
5.48%
Other
57.83%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.95%
VR Adviser, LLC
8.57%
Fairmount Funds Management LLC
7.65%
Viking Global Investors LP
5.51%
Deep Track Capital LP
5.48%
Other
57.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.93%
Hedge Fund
28.88%
Investment Advisor/Hedge Fund
24.62%
Venture Capital
9.46%
Individual Investor
2.95%
Private Equity
2.62%
Research Firm
0.67%
Bank and Trust
0.07%
Pension Fund
0.02%
Other
1.79%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
167
38.19M
78.94%
+1.39M
2025Q2
134
34.13M
91.17%
-374.64K
2025Q1
126
33.17M
88.60%
-411.60K
2024Q4
108
32.03M
91.52%
+5.95M
2024Q3
82
24.69M
76.77%
+23.20M
2024Q2
63
1.18M
97.69%
+158.22K
2024Q1
51
615.50K
50.93%
-73.00K
2023Q4
52
638.70K
53.19%
-26.99K
2023Q3
57
620.09K
51.64%
-75.36K
2023Q2
59
581.79K
48.45%
-59.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.62M
11.61%
+54.82K
+0.99%
Jun 30, 2025
VR Adviser, LLC
4.15M
8.57%
--
--
Jun 30, 2025
Fairmount Funds Management LLC
3.71M
7.66%
+333.34K
+9.89%
Sep 17, 2025
Viking Global Investors LP
2.67M
5.51%
+2.67M
--
Sep 17, 2025
Deep Track Capital LP
1.92M
3.97%
+22.02K
+1.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.83M
3.78%
+1.10M
+150.66%
Jun 30, 2025
RTW Investments L.P.
1.95M
4.02%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.82M
3.76%
+179.87K
+10.99%
Jun 30, 2025
Commodore Capital LP
1.42M
2.93%
--
--
Jun 30, 2025
Braidwell LP
1.52M
3.15%
-47.58K
-3.03%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Health Innovation Active ETF
0.21%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.11%
State Street SPDR S&P Biotech ETF
0.11%
iShares Biotechnology ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
iShares Russell 2000 Value ETF
0.05%
Proshares Ultra Russell 2000
0.03%
View more
iShares Health Innovation Active ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
State Street SPDR S&P Biotech ETF
Proportion0.11%
iShares Biotechnology ETF
Proportion0.08%
Avantis US Small Cap Equity ETF
Proportion0.06%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0.05%
Proshares Ultra Russell 2000
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 23, 2024
Merger
12→1
Aug 23, 2024
Merger
12→1
Aug 23, 2024
Merger
12→1
Aug 23, 2024
Merger
12→1
Date
Type
Ratio
Aug 23, 2024
Merger
12→1
Aug 23, 2024
Merger
12→1
Aug 23, 2024
Merger
12→1
Aug 23, 2024
Merger
12→1
FAQs
Who are the top five shareholders of Oruka Therapeutics Inc?
The top five shareholders of Oruka Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 5.62M shares, accounting for 11.61% of the total shares.
VR Adviser, LLC holds 4.15M shares, accounting for 8.57% of the total shares.
Fairmount Funds Management LLC holds 3.71M shares, accounting for 7.66% of the total shares.
Viking Global Investors LP holds 2.67M shares, accounting for 5.51% of the total shares.
Deep Track Capital LP holds 1.92M shares, accounting for 3.97% of the total shares.
Fidelity Management & Research Company LLC holds 5.62M shares, accounting for 11.61% of the total shares.
VR Adviser, LLC holds 4.15M shares, accounting for 8.57% of the total shares.
Fairmount Funds Management LLC holds 3.71M shares, accounting for 7.66% of the total shares.
Viking Global Investors LP holds 2.67M shares, accounting for 5.51% of the total shares.
Deep Track Capital LP holds 1.92M shares, accounting for 3.97% of the total shares.
What are the top three shareholder types of Oruka Therapeutics Inc?
The top three shareholder types of Oruka Therapeutics Inc are:
Fidelity Management & Research Company LLC
VR Adviser, LLC
Fairmount Funds Management LLC
Fidelity Management & Research Company LLC
VR Adviser, LLC
Fairmount Funds Management LLC
How many institutions hold shares of Oruka Therapeutics Inc (ORKA)?
As of 2025Q3, 167 institutions hold shares of Oruka Therapeutics Inc, with a combined market value of approximately 38.19M, accounting for 78.94% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.23%.
What is the biggest source of revenue for Oruka Therapeutics Inc?
In --, the -- business generated the highest revenue for Oruka Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
